Effect of canagliflozin on the disposition index, a marker of pancreatic beta-cell function, in type 2 diabetic patients: a randomized controlled study
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs Canagliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CANDI-beta STUDY
- 03 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2018 Status changed from not yet recruiting to recruiting.
- 29 Mar 2018 New trial record